C109 NEW TECHNOLOGY IN SLEEP: DIAGNOSTICS AND THERAPEUTICS: Diet, Exercise And Armodafinil For Obstructive Sleep Apnea Patients Unable To Tolerate Standard Treatments (dear). A Randomized, Parallel Group, Factorial Trial

Obesity is a modifiable risk factor for OSA, but weight loss takes time while often the primary presenting symptom of excessive daytime sleepiness remains. Methods: Overweight patients (BMI>27kg/m2) with at least moderate OSA (AHI>15) who had rejected CPAP or MAS and had no major comorbid cond...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Hoyos, C M, Chapman, J, Cayanan, E A, Serinel, Y, Yee, B J, Wong, K K, Grunstein, R R, Marshall, N
Format: Article
Language:English
Subjects:
Diet
Exercise
Health risk assessment
Medical diagnosis
Sleep
Sleep apnea
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obesity is a modifiable risk factor for OSA, but weight loss takes time while often the primary presenting symptom of excessive daytime sleepiness remains. Methods: Overweight patients (BMI>27kg/m2) with at least moderate OSA (AHI>15) who had rejected CPAP or MAS and had no major comorbid conditions were randomized concurrently into one of two 6 month diets (LGHP vs AGHE) with follow-up to 12 months and 150mg armodafinil or matching placebo daily for the first 6 months.
ISSN:1073-449X
1535-4970